• bevacizumab;
  • recurrent anaplastic oligodendroglioma;
  • alkylator;
  • chemotherapy;
  • refractory


  1. Top of page
  2. Abstract
  6. Conflict of Interest Disclosures
  7. References


A retrospective evaluation of single agent bevacizumab was carried out in adults with recurrent alkylator-refractory 1p19q codeleted anaplastic oligodendrogliomas (AO) with an objective of determining progression-free survival (PFS). There is no standard therapy for alkylator-resistant AO, and hence a need exists for new therapies.


Twenty-two patients aged 24 to 60 years with recurrent AO were treated. All patients had previously been treated with surgery, radiotherapy, adjuvant chemotherapy (temozolomide, 17; carmustine wafers, 4; carmustine, 1), and 1 salvage regimen (procarbazine, lomustine, and vincristine, 15; temozolomide, 6; carmustine wafers, 1). Eleven patients underwent repeat surgery. Patients were treated at second recurrence with bevacizumab, once every 2 weeks, defined as a single cycle. Neurological evaluation was performed every 2 weeks, and neuroradiographic assessment was made after the initial 2 cycles of bevacizumab and subsequently after every 4 cycles of bevacizumab.


A total of 391 cycles of bevacizumab (median, 14.5 cycles; range, 2-39 cycles) were administered. Bevacizumab-related toxicity included fatigue (14 patients; 4 grade 3), leukopenia (9; 1 grade 3), anemia (5; 0 grade 3), hypertension (5; 1 grade 3), deep vein thrombosis (4; 1 grade 3), and wound dehiscence (2; 1 grade 3). Fifteen (68%) patients demonstrated a partial radiographic response, 1 (5.0%) demonstrated stable disease, and 6 (27%) demonstrated progressive disease after 2 cycles of bevacizumab. Time to tumor progression ranged from 1 to 18 months (median, 6.75 months). Survival ranged from 3 to 19 months (median, 8.5 months). Six-month and 12-month PFS were 68% and 23%, respectively.


Bevacizumab demonstrated efficacy and acceptable toxicity in this cohort of adults with recurrent 1p19q codeleted alkylator-refractory AO. Cancer 2009. © 2009 American Cancer Society.

The treatment of recurrent anaplastic oligodendroglial tumors (anaplastic oligodendroglioma [AO], anaplastic oligoastrocytoma [AOA]) like all high grade gliomas (HGG) is problematic, as only partially effective therapeutic modalities are available, and there is a lack of a standard therapy for recurrence. These therapies include chemotherapy, radioactive implants, stereotactic radiotherapies, targeted therapy, and reoperation.1-27 Chemotherapy for recurrent HGG is of modest benefit, primarily because response to chemotherapy is of limited duration. In an analysis of 8 institutional phase 2 studies of chemotherapy for recurrent HGG, Wong reported that response rates in recurrent anaplastic astrocytomas were 14%, and progression-free survival (PFS) at 6 months (PFS-6) was 31%.13 Those drugs most active are the nitrosoureas, such as carmustine (BCNU) and lomustine (CCNU), in addition to temozolomide (TMZ), procarbazine, cis-retinoic acid, and platinum compounds.1, 2, 4, 5, 10-12, 14, 17, 23-27 Bevacizumab, with or without irinotecan (CPT-11), has activity in recurrent glioblastoma (GBM), and a small data set exists for activity as well in recurrent anaplastic gliomas.28-34

The objective of this single institution retrospective analysis was to observe whether bevacizumab as a single agent, given every 2 weeks, could significantly delay progression in patients with neuroradiographically recurrent 1p19q codeleted AO/AOA as determined by PFS-6. Twenty-two adult patients with recurrent supratentorial AO/AOA previously treated with surgery, radiotherapy, and alkylator-based chemotherapy (TMZ and PCV [procarbazine, CCNU, and vincristine]) were retrospectively evaluated.


  1. Top of page
  2. Abstract
  6. Conflict of Interest Disclosures
  7. References

The retrospective analysis was performed at the University of Washington and the University of South Florida, H. Lee Moffitt Cancer Center and Research Institute. The trial commenced in January 2005 and closed in March 2008. The retrospective analysis was conducted without industry support, and approval and funding for off-label use of bevacizumab was obtained from the patients' insurance carrier. Patients were apprised of the nonstandard care treatment and agreed to bevacizumab treatment after disclosure of potential risks and benefits.

Objectives and Endpoints

The objective was to determine the efficacy of bevacizumab in the treatment of patients with TMZ-refractory recurrent 1p19q codeleted AO/AOA. The primary endpoint was PFS-6. Secondary endpoints included overall survival (OS), time to progression, and response. Toxicity was evaluated in all eligible patients receiving at least 1 cycle of bevacizumab.


Patients were required to have a histologically proven 1p19q codeleted AO or AOA that was recurrent neuroradiographically. Patients must have progressed after definitive radiotherapy and alkylator-based chemotherapy (TMZ and nitrosoureas). Patients may have had no more than 1 salvage chemotherapy regimen. At least 4 (if prior TMZ treatment), 6 (if prior PCV/BCNU treatment), or 12 (if prior carmustine wafers treatment) weeks must have elapsed since the last dose of chemotherapy, and patients must have recovered from the adverse effects of prior therapy. Patients could not have received prior bevacizumab therapy. Patients were required to have radiographically measurable intracranial disease wherein recurrent tumor was bidimensionally measurable (at least 1 cm × 1 cm) by cranial contrast-enhanced magnetic resonance imaging (MRI). Histological confirmation of tumor recurrence was not required for entry into the study. Pregnant or lactating women were not permitted to participate. Patients of childbearing potential were required to implement adequate contraceptive measures during participation in this study. Patients must have had a Karnofsky performance status ≥60 and a life expectancy >3 months.

Adequate hematologic, renal, and hepatic functions were required and were defined by the following: absolute granulocyte count >1500/dL or white blood cell count >4000/dL, platelet count >100,000/dL, total bilirubin level <1.8 mg/dL, transaminase level <4× the upper limit of normal, and creatinine concentration <1.8 mg/dL (or creatinine clearance ≥60 mL/m2/1.73).

All patients were aware of the neoplastic nature of their disease and willingly agreed to participate after being informed of the procedures to be used, experimental nature of the therapy, alternatives, potential benefits, side effects, risk, and discomforts. Patients with carcinomatous meningitis were not eligible. No serious concurrent medical illnesses or active infection could be present that would jeopardize the ability of the patient to receive bevacizumab therapy. Patients could not have an active concomitant malignancy except skin cancer (squamous cell or basal cell). Patients could range in age from 18 to 80 years.

Drug Schedule

Bevacizumab (Avastin; Genentech Pharmaceuticals, South San Francisco, Calif) was administered as a single agent to all patients at a dose of 10 mg/kg regardless of antiepileptic drug use. Bevacizumab was administered intravenously over 30 minutes on a single day.28-34 Concurrent dexamethasone was permitted for control of neurologic signs and symptoms. Bevacizumab was administered without premedication or prechemotherapy hydration. No posthydration intravenous fluids were administered. In patients having undergone re-resection, bevacizumab commenced 4 to 6 weeks after surgery and after establishment of normal craniotomy wound healing.

A cycle of therapy was operationally defined as 14 days, during which bevacizumab was administered on Day 1. Treatment with bevacizumab was repeated every 14 days from Day 1, provided that all hematologic toxicity from the previous cycle had resolved to grade 2 or less, and all nonhematologic toxicity had recovered to either grade 1 or less. If recovery had not occurred by Day 14, the subsequent cycle of bevacizumab was delayed until these criteria were met. All toxicities including hematologic because of bevacizumab therapy were rated according to the National Institutes of Health Common Toxicity Criteria (version 3.0).

No bevacizumab dose escalations were permitted. Dose reduction for toxicity was by 25% in patients with grade ≥3 toxicity, and only 1 dose reduction was allowed. Patients having grade 3 toxicity of any type after 1 dose reduction discontinued bevacizumab, as did patients delayed more than 2 weeks from the next scheduled chemotherapy.

Method of Evaluation

Laboratory tests (complete blood counts, basic metabolic panel, and urinary protein to creatinine ratio) were obtained biweekly, and neurological examination was performed every other week. Contrast-enhanced cranial MRI was performed after the initial 2 cycles of bevacizumab and thereafter every 8 weeks (and after 4 subsequent cycles of bevacizumab).

Neuroradiographic response criteria as defined by Macdonald et al were used.21, 28-34 Complete response (CR) was defined as the disappearance of all enhancing (contrast-enhancing tumor volume [CTV]) or nonenhancing tumor (MRI-defined fluid-attenuated inversion recovery tumor volume [FTV]) on consecutive MRI scans at least 1 month apart, with the patient off corticosteroids and neurologically stable or improved. Partial response (PR) was defined as a >50% reduction in the size of tumor (CTV; FTV) on consecutive MRI scans at least 1 month apart, with the corticosteroid dose stable or decreased and the patient neurologically stable or improved. Progressive disease (PD) was defined as a >25% increase in the size of tumor (CTV; FTV) or any new tumor on MRI scans, or the patient neurologically worse with a stable or increased corticosteroid dose. Stable disease (SD) was defined as all other situations. SD response as with CR and PR required a confirmation MRI scan 1 month after documenting best response.

In patients with SD, PR, or CR, 4 additional cycles of bevacizumab was to be administered, after which patients were assessed again as described. Patients were continued on bevacizumab therapy until documentation of PD, at which time patients were removed from bevacizumab treatment and were either monitored or offered alternative therapy.

PFS and OS were defined as the time from the first day of treatment with bevacizumab until progression or death (PFS) or death (OS). Patients were removed from bevacizumab treatment if there was progressive disease, development of unacceptable toxicity, patient refusal, or noncompliance with protocol requirements.


The objective of this retrospective analysis was to determine whether single agent bevacizumab could significantly delay progression in patients with recurrent AO/AOA. Historical values were obtained from analysis of a database of 350 patients with recurrent HGG (125 anaplastic gliomas [AG]) treated on consecutive prospective phase II trials, in which PFS-6 was 31% for AG.13 The authors recognize that this comparison is only partially relevant, as the trials by Wong analyzed only anaplastic astrocytoma and not AO and AOA. Nonetheless, there are no other published data sets regarding outcome of recurrent AO/AOA. The median survival, time to progression, and the associated 95% confidence intervals (CIs) were computed. Kaplan-Meier plots were constructed to display the estimated probabilities of overall survival and time to progression.35-39


  1. Top of page
  2. Abstract
  6. Conflict of Interest Disclosures
  7. References

Study Population

Twenty-two patients (13 men; 9 women) aged 24 to 60 years (median, 51 years), with recurrent 1p19q codeleted (by fluorescence in situ hybridization [FISH]) AO/AOA (original pathology including FISH analysis was reviewed and confirmed in all cases by the participating institutions) were treated with bevacizumab (Table 1). Recurrent AO/AOA was defined by objective neuroradiographic progression (>25% increase in tumor size), as compared with prior baseline neuroradiographic images using the criteria reported by Macdonald.21 All neuroradiography was locally reviewed by 2 neuroradiologists blinded to treatment and by the participating neuro-oncologist (M.C.C.). All patients underwent cranial MRI demonstrating progressive disease within 2 weeks of bevacizumab administration. Eleven (50%) patients underwent a reoperation (subtotal in all but 1) in which repeat tumor histology was consistent with 1p19q codeleted AO or AOA. Notwithstanding reoperation, residual disease was measurable (median tumor volume 2 cm2) in all patients. The single patient with a complete re-resection subsequently progressed and had radiographically measurable disease.

Table 1. Recurrent Anaplastic Oligodendroglioma: Salvage Therapy Bevacizumab
PatientSexAge, yTumor LocationAdjuvant TherapyPrior Salvage TherapyBevacizumab Salvage Therapy
SurgeryRadiation, GyChemotherapy Cycles (Best Response)Chemotherapy Cycles (Best Response)/ Repeat SurgeryNo. of CyclesResponse/ Duration, moSurvival, mo
  1. M indicates men; Gy, grays; R, right; STR, subtotal resection; TMZ, temozolomide; PR, partial response; PCV, procarbazine, lomustine, vincristine; SD, stable disease; GTR, gross total resection; PD, progressive disease; W, women; L, left; Bx, biopsy; BCNU, carmustine.

1M24R FrontalSTR60TMZ 12 (PR)PCV 2 (SD)6SD/35
2M28R ParietalGTR60TMZ 6 (SD)PCV 1 (PD)13PR/68
3W29L FrontalGTR59TMZ 6 (SD)PCV 2 (SD)20PR/910
4M35L ParietalSTR60TMZ 12 (SD)PCV 1 (PD)/STR x118PR/810
5M42BifrontalBx60TMZ 12 (PR)PCV 4 (PR)13PR/67
6M43L FrontalGTR60Carmustine wafers 1 (SD)TMZ 6 (SD)2PD/24
7W47L OccipitalSTR60BCNU 6 (PR)TMZ 5 (SD)/STR x13PD/1.53
8M47L FrontalGTR59TMZ 6 (SD)PCV 3 (SD)13PR/67
9W48R FrontotemporalSTR59TMZ 12 (PR)PCV 4 (PR)/STR x126PR/1214
10M49L FrontalGTR60Carmustine wafers 1 (SD)TMZ 4 (SD)16PR/7.59
11W50R TemporalGTR60TMZ 6 (SD)PCV 3 (PR)/STR x113PR/68
12W52R ParietalBx60TMZ 12 (SD)PCV 4 (SD)/STR x13PD/1.53
13M52L ParietalBx60TMZ 12 (SD)PCV 1 (PD)/STR x119PD/8.510
14M53R TemporalGTR59Carmustine wafers 1 (SD)TMZ 6 (PR)/STR x123PR/10.512
15W54R FrontoparietalSTR60TMZ 12 (PR)Carmustine wafers 1 (SD)/GTR x18SD/45
16M56R FrontalGTR60TMZ 6 (SD)PCV 1 (PD)17PR/810
17W56L FrontalGTR60Carmustine wafers 1 (SD)TMZ 8 (PR)/STR x130PR/1415
18M57R TemporalGTR60TMZ 6 (SD)PCV 4 (PR)19PR/8.510
19M58R ParietalSTR60TMZ 12 (PR)PCV 2 (PD)/STR x130PR/1415
20W59L FrontotemporalSTR60TMZ 12 (SD)PCV 2 (PD)39PR/1819
21M59R FrontalGTR60TMZ 6 (SD)PCV 1 (PD)/STR x12PD/13
22W60L ParietalBx59.4TMZ 12 (PR)TMZ 6 (SD)3PD/1.53

Patients presented at the time of tumor recurrence with the following signs and symptoms: increased intracranial pressure as manifested by increasing headache (n = 16), worsening seizures (n = 10), altered mental status (n = 4), progressive hemiparesis (n = 4), new onset homonymous hemianopsia (n = 1), and gait ataxia (n = 1). Patient performance status using the Karnofsky scale ranged from 60 to 100 (median, 80) at the time of documented tumor recurrence and initiation of bevacizumab therapy. Tumor locations are delineated in Tables 1 and 2. Pathology (reviewed by a panel of 2 neuropathologists) showed all tumors to be AO/AOA by World Health Organization criteria.

Table 2. Characteristics of Study Patients
VariablesNo. of Patients%
  1. GTR indicates gross total resection; STR, subtotal resection; TMZ, temozolomide; BCNU, carmustine; PCV, procarbazine, lomustine, vincristine.

Total patients22100
Age, y  
 Median (range)51 (24-60) 
Location of tumor  
Extent of initial surgery  
Up-front chemotherapy  
 Carmustine wafers418
Salvage chemotherapy  
 Carmustine wafers15
Reoperation at recurrence  
No. of cycles of bevacizumab  
 ≤3 cycles523
 >13 cycles1568
 Median (range)14.5 (2-39) 
Best response to bevacizumab treatment  
 Complete response00
 Partial response1464
 Stable disease29
 Progressive disease627

Prior treatment is shown in Tables 1 and 2. All patients had previously been treated with up-front limited-field radiotherapy using conventional fractionated radiotherapy in which 1.8 to 2.0 grays (Gy) was administered daily, with a median tumor dose of 60 Gy (range, 59-60 Gy). No patients were treated with stereotactic radiotherapy.

All patients were treated with bevacizumab after failure of alkylator-based therapy (Table 1 and 2) as demonstrated by neuroradiographic progression (in all patients) or clinical disease progression (60% of patients). All patients began bevacizumab at second recurrence with a median time to initiation of bevacizumab after initial surgery of 52 months, with a range of 16 to 113 months. A total of 391 cycles of bevacizumab were administered. A minimum of 2 cycles of bevacizumab was administered to each patient, with a median of 14.5 cycles (range, 2-39 cycles). Bevacizumab was administered at the prescribed dose in all patients. No other antiglioma agents aside from dexamethasone were used during the study. Oral dexamethasone was used concurrently in 14 patients and was increased in 6 patients with clinical disease progression. Dexamethasone dose was decreased in 15 patients with a neuroradiographic response and as patient clinical status permitted.

Six patients received cyclophosphamide chemotherapy after progression on bevacizumab, although none responded and all progressed rapidly and died of complications of their primary brain tumor (median survival, 2 months). No patient after demonstrating progression on bevacizumab-only therapy continued on bevacizumab when changed to cyclophosphamide.


Toxicity was recorded for all grades for all patients by type using the National Cancer Institute common toxicity criteria (version 3.0). Table 3 lists all grade 2 to 5 toxicity observed with each figure representing the sum of the highest grade of toxicity attained, per toxicity, per cycle for all patients. A total of 391 treatment cycles were administered, of which there were 9 grade 3 adverse events (AEs) in 9 (41%) patients and no grade 4 or 5 AEs. There were no treatment-related transfusions, episodes of febrile neutropenia, or treatment-related deaths. Two patients developed asymptomatic small intratumoral hemorrhages, and in both bevacizumab therapy was continued without evidence of hemorrhagic progression by serial magnetic resonance images. One patient with a craniotomy wound dehiscence requiring surgery prematurely terminated bevacizumab therapy.

Table 3. Bevacizumab in Recurrent Anaplastic Oligodendroglioma: Toxicity
ToxicityGrade 2Grade 3Grade 4Grade 5Total
Intracranial hemorrhage20002
Infection without neutropenia21003
Wound dehiscence11002


All patients were assessable for response and survival. After 2 cycles of bevacizumab, 6 (27%) patients demonstrated progressive disease and discontinued therapy. Fifteen (68%) patients received ≥13 cycles of therapy. At the conclusion of bevacizumab, Karnofsky performance status ranged from 40 to 70, with a median of 60 in the entire study group. PFS ranged from 3 to 18 months (Fig. 1), with an estimated median of 8.0 months (95% CI, 7.03-8.97). Patients who failed to respond to bevacizumab were offered alternative or supportive therapy. Survival in the entire cohort ranged from 3 months to 19 months, with an estimated median of 8.0 months (95% CI, 6.28-9.72) (Fig. 1). The probability of survival at 6 and 12 months was 68% and 23%. All patients have died, and all deaths were directly attributable to the effects of progressive intracranial tumor.

thumbnail image

Figure 1. Kaplan-Meier curve shows patients with recurrent alkylator-refractory anaplastic oligodendroglioma treated with bevacizumab. Dashed line indicates progression-free survival. Solid line indicates overall survival.

Download figure to PowerPoint

No (0%) patient demonstrated a complete response, 14 (64%) patients demonstrated a neuroradiographic partial response (95% CI, 44%-84%), and 1 (5%) patient demonstrated stable disease (95% CI, −4%-13%). In patients with a neuroradiographic response or stable disease (16; 73%), median time to tumor progression was 8 months (range, 3-18 months; 95% CI, 7.02-8.97). Fifteen (68%) patients were able to reduce dexamethasone dose, and in 10 (45%) patients, dexamethasone was discontinued.

There was no association observed between response to bevacizumab and response to the prior alkylator-based regimens. In addition, no difference was seen in the pretreatment tumor volume in patients with either a bevacizumab partial response or stable disease as compared with patients with progressive disease.


  1. Top of page
  2. Abstract
  6. Conflict of Interest Disclosures
  7. References

How best to manage recurrent AO/AOA remains ill-defined notwithstanding a variety of studies. Most studies, however, are small nonrandomized trials comparing outcome to historical controls (similar to the present retrospective analysis). Only a minority of patients with recurrent AO/AOA (only 1 in the present study notwithstanding 50% of patients underwent re-resection) are candidates for image-verified complete or near complete re-resection followed by carmustine wafer implantation.26 Therefore, the majority of patients if desirous of further therapy are offered chemotherapy. PCV has been used in TMZ-refractory AO/AOA in an European Organization for Research and Treatment of Cancer trial with response rates of 17% and PFS-6 of 25%.40, 41 By way of comparison, in the present analysis all patients had in addition to TMZ chemotherapy been treated with a nitrosourea (BCNU, carmustine wafers, or PCV), and consequently at time of recurrence, an alternative non–alkylator-based therapy was attractive. CPT-11 (Camptosar, Pfizer Pharmaceuticals, Princeton, NJ) has been used for recurrent AO with response rates of 23% and 33% PFS-6, results again less compelling than the present study.24, 42-47 Similarly, carboplatin (with or without teniposide) has been used in several trials for recurrent AO with response rates of 9% to 13% and 35% PFS-6, results less robust than the present analysis.14, 15, 48, 49

The present retrospective analysis was directed at the 1p19q codeleted AO/AOA population who had failed prior alkylator-based chemotherapy (both TMZ and nitrosoureas) and for whom further treatment appeared warranted. Treatment with bevacizumab did not require histological proof of recurrent AO/AOA, and the possibility of radiation necrosis as opposed to recurrent tumor is possible. This appears unlikely for the following reasons. No patient received stereotactic radiotherapy, and the risk of radiation necrosis is <5% in patients treated with standard fractionated radiotherapy. Furthermore, 11 (50%) patients underwent 2-deoxy-2[F-18]fluoro-D-glucose positron emission tomography, and 10 (45%) patients underwent magnetic resonance spectroscopy in which recurrent viable tumor was radiographically confirmed. Lastly, histopathology was reconfirmed in 11 (50%) patients who underwent reoperation. The retrospective analysis did not require re-examination of histology, and therefore a proportion of patients assumed to have AO/AOA may have progressed to glioblastoma. Therefore the present cohort may be evaluating both patients with AO/AOA and those with secondary glioblastoma.

Although multiple antiangiogenic strategies are being explored, with respect to antiglioma based therapy, only 2 have entered clinical practice, ligand-based antagonist therapy using monoclonal antibodies such as bevacizumab and receptor-based antagonist therapy with tyrosine kinase inhibitors such as AZD2171.28-34, 50 The use of bevacizumab has been predominantly with cytotoxic chemotherapy (CPT-11 or carboplatin) based on 2 concepts: interruption of vascular endothelial growth factor (VEGF) signaling leading to sensitization or reversal of cytotoxic drug resistance, and improvement in cytotoxic drug vascular access through vascular normalization and decrease in tumor interstitial pressure. This combinatorial rationale is compelling for non-neural cancers, for example colorectal, nonsmall cell lung, and breast cancer, although it has not been convincingly demonstrated for HGG.34

The available data for antiangiogenic therapy in HGG are most robust for ligand-based VEGF antagonism and are based on several single institution studies, many of which are retrospective.28-34 With 1 exception, these studies have used combinatorial therapy and treated predominantly GBM (among a total of 344 patients treated, 45 [13%] were AG). Data regarding response rates and survival for AG treated with bevacizumab are difficult to determine, as outcome is often reported for both GBM and AG. On the basis of the 2 largest studies using bevacizumab for recurrent AG (n = 30), response rates vary with complete response to bevacizumab plus therapy in 0%, partial response in 34% to 67%, and stable disease in 25% to 30% of patients.31, 33 PFS varies as well (median, 30 weeks; PFS-6, 32%-56%). These results with bevacizumab can be compared with TMZ for recurrent TMZ-naive AG (response rate, 35%; PFS-6, 44%; median overall survival, 13.6 months) and an aggregate series of 8 phase II trials for recurrent AG (pre-TMZ) from the M. D. Anderson Cancer Center (response rate, 14%; PFS-6, 31%; median overall survival, 47 weeks).13, 16 In the present analysis and compared with the abovementioned historical controls, bevacizumab therapy improved both response rate (68%) and PFS-6 (68%) in patients with recurrent alkylator-refractory AO/AOA, but had no clear survival benefit (median overall survival, 8 months). Bevacizumab therapy therefore appears to increase response of recurrent AG by 2-fold without a clear benefit with respect to PFS or OS. Notwithstanding the limited literature, based on these data and historical comparisons, bevacizumab plus therapy has become the current treatment of choice for recurrent AG. In a provocative phase II study comparing bevacizumab with or without CPT-11 in patients with recurrent GBM (the only randomized trial in recurrent gliomas), results suggest similar outcomes between treatment arms, raising the question of what added value is provided by CPT-11.34 The authors recognize that these data remain preliminary, as they have been published only in abstract form and may change upon publication.

In these various studies including the present study, toxicity of bevacizumab plus therapy have been modest and comprised primarily of low grade bleeding (epistaxis, vaginal, or oral cavity), proteinuria, impaired wound healing, and hypertension.28-34 The majority of antiangiogenic side effects appear to be a consequence of on-target actions of this class of agents and reflect disruption of VEGF in normal tissue. Rare serious side effects include gastrointestinal perforation, intratumoral hemorrhage, and craniotomy or central venous line wound dehiscence (each with <1% incidence). The high incidence of deep vein thrombosis and pulmonary embolism in patients with HGG confounds separation as an independent toxicity of antiangiogenic therapies, although antiangiogenic therapy may aggravate this thrombogenic predisposition.51-54 A retrospective review of bevacizumab plus therapy in patients with recurrent HGG suggests that concurrent use of anticoagulation appears safe without an apparent increased risk of hemorrhage.33

In conclusion, bevacizumab as a single agent used at this dose and schedule in patients with previously treated alkylator chemotherapy–refractory recurrent 1p19q codeleted AO appears of benefit (as determined by response rate and PFS-6) for recurrent alkylator-refractory AO/AOA. Regarding the primary endpoint (PFS-6), the results exceed the 20% threshold for success, assuming a 20% improvement as compared with the database reported by Wong (anaplastic astrocytoma: expected 31%; observed 68%).13 More problematic, however, is the lack of OS benefit with bevacizumab for recurrent AG. A prospective trial evaluating bevacizumab for recurrent AG using quality of life endpoints as well as traditional outcome measures is required to determine whether an advantage for bevacizumab therapy exists compared with alternative chemotherapy strategies.

Conflict of Interest Disclosures

  1. Top of page
  2. Abstract
  6. Conflict of Interest Disclosures
  7. References

The authors report no conflict of interest.


  1. Top of page
  2. Abstract
  6. Conflict of Interest Disclosures
  7. References
  • 1
    The Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research Council Trial. J Clin Oncol. 2000; 19: 509-518.
  • 2
    Prados MD, Scott C, Curran WJ Jr, Nelson DF, Leibel S, Kramer S. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol. 1999; 17: 3389-3395.
  • 3
    Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable Carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003; 5: 79-88.
  • 4
    Grossman SA, O'Neill A, Grunnet M, et al. Phase III study comparing 3 cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol. 2003; 21: 1485-1491.
  • 5
    Prados MD, Levin V. Biology and treatment of malignant glioma. Semin Oncol. 2000; 27( suppl 3): 1-10.
  • 6
    Gutin PH, Prados MD, Phillips TL, et al. External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG Study 6G82-2. Int J Radiat Oncol Biol Phys. 1991; 21: 601.
  • 7
    Kornblith PD, Welch WC, Bradley MK. The future of therapy for glioblastoma. Surg Neurol. 1993; 39: 538-543.
  • 8
    Loeffler JS, Alexander E, Shea WM, et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol. 1992; 10: 1379-1385.
  • 9
    Prados MD, Gutin PH, Phillips TL, et al. Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience. Int J Radiat Oncol Biol Phys. 1992; 24: 593.
  • 10
    Levin VA, Silver P, Hannigan J, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990; 18: 321-324.
  • 11
    Stewart LA. Chemotherapy in adult high-grade glioma: a systemic review and meta-analysis of individual patient data from 12 randomized trials. Lancet. 2002; 359: 1011-1018.
  • 12
    Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy and without chemotherapy for malignant gliomas in adults. Cancer. 1993; 71: 2585-2597.
  • 13
    Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17: 2572-2578.
  • 14
    Yung WKA, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant gliomas: a phase II study. J Clin Oncol. 1991; 9: 860.
  • 15
    Allen JC, Walker R, Luks E, et al. Carboplatin and recurrent childhood brain tumors. J Clin Oncol. 1987; 5: 759-763.
  • 16
    Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999; 17: 2762-2771.
  • 17
    See SJ, Levin VA, Yung A, et al. 13-cis-Retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncol. 2004; 6: 253-258.
  • 18
    Allen JC, Helson L. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg. 1981; 55: 749-756.
  • 19
    Longee DC, Friedman HS, Albright RE, et al. Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg. 1990; 72: 583-588.
  • 20
    Chamberlain MC, Tsao-Wei D. Recurrent glioblastoma multiforme: salvage therapy with cyclophosphamide. Cancer. 2004; 100: 1213-1220.
  • 21
    Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 1277-1280.
  • 22
    Prados MD, Gutin PH, Phillips TL, et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys. 1992; 23: 3-8.
  • 23
    Tortosa A, Vinolas N, Villa S, et al. Prognostic implications of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer. 2003; 97: 1063-1071.
  • 24
    Chamberlain M, Glantz MJ. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. Cancer. 2008; 112: 2038-2045.
  • 25
    Stupp R, Mason WP, Van Den Bent MJ, et al. Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme. Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trial Groups. J Clin Oncol. 2004; 22: 1s.
  • 26
    Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995; 345: 1008-1012.
  • 27
    Jaeckle KA, Hess KR, Yung A, et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2003; 21: 2305-2311.
  • 28
    Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol. 2005; 7: 369.
  • 29
    Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006; 66: 1258-1260.
  • 30
    Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13: 1253-1259.
  • 31
    Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25: 4722-4729.
  • 32
    Chen C, Silverman DHS, Geist C, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007; 25: 4714-4721.
  • 33
    Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant glioma: efficacy, toxicity and patterns of recurrence. Neurology. 2008; 70: 779-787.
  • 34
    Cloughesy T, Prados MD, Mikkelsen T, et al. A phase 2 randomized non-comparative clinical trial of the effect of bevacizumab alone or in combination with irinotecan on 6-month progression free survival in recurrent treatment refractory glioblastoma [abstract]. J Clin Oncol. 2008; 26: 91s.
  • 35
    Miller RG Jr. Survival Analysis. New York: John Wiley & Sons; 1981: 114-118.
  • 36
    Pike MC. Contribution to the discussion on the paper by R. Peto and J. Peto, “Asymptotically efficient rank invariant procedures.” J R Stat Soc (Series A). 1972; 135: 201-203.
  • 37
    Berry G, Kitchin RM, Mock PA. A comparison of two simple hazard ratio estimators based on the logrank test. Stat Med. 1991; 10: 749-755.
  • 38
    Lawless JF. Statistical Models and Methods for Lifetime Data. New York: John Wiley & Sons; 1982: 345-354.
  • 39
    Kaplan EL, Meier P. Nonparametric estimation form incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 40
    Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Oncology Group trial 9402. J Clin Oncol. 2006; 24: 2707-2714.
  • 41
    van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine and vincristine improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer Phase III trial. J Clin Oncol. 2006; 24: 2715-2722.
  • 42
    Batchelor TT, Gilbert MR, Supko JG, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol. 2004; 6: 21-27.
  • 43
    Buckner JC, Reid JM, Wright K, et al. Irinotecan in the treatment of glioma patients: current and future studies of the North Cancer Central Treatment Group. Cancer. 2003; 97: 2352-2358.
  • 44
    Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol. 2002; 56: 183-188.
  • 45
    Cloughesy TF, Filka E, Kuhn J, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every 3-week regimen. Cancer. 2003; 97: 2381-2386.
  • 46
    Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with progressive malignant glioma. J Clin Oncol. 1999; 17: 1516-1525.
  • 47
    Prados MD, Yung WKA, Jaeckle KA, et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004; 6: 44-54.
  • 48
    Soffieti R, Nobile M, Rida F, et al. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV chemotherapy: a phase II study. Cancer. 2004; 15: 807-813.
  • 49
    Brandes AA, Basso U, Vastola F, et al. Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. Ann Oncol. 2003; 14: 1727-1731.
  • 50
    Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007; 11: 83-95.
  • 51
    Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur J Cancer. 1997; 33: 1592-1596.
  • 52
    Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 2000; 89: 640-646.
  • 53
    Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007; l06: 601-608.
  • 54
    Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol. 2007; 9: 89-95.